RPRX vs. WAT: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at RPRX and WAT, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | RPRX | WAT |
|---|---|---|
| Company Name | Royalty Pharma plc | Waters Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Life Sciences Tools & Services |
| Market Capitalization | 21.51 billion USD | 17.66 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | June 16, 2020 | November 17, 1995 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of RPRX and WAT by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | RPRX | WAT |
|---|---|---|
| 5-Day Price Return | 1.04% | 1.09% |
| 13-Week Price Return | 7.68% | -17.24% |
| 26-Week Price Return | 13.62% | -21.73% |
| 52-Week Price Return | 34.16% | -12.79% |
| Month-to-Date Return | 0.22% | 2.76% |
| Year-to-Date Return | 44.57% | -20.01% |
| 10-Day Avg. Volume | 3.37M | 0.62M |
| 3-Month Avg. Volume | 4.10M | 0.68M |
| 3-Month Volatility | 21.06% | 38.48% |
| Beta | 0.59 | 1.06 |
Profitability
Return on Equity (TTM)
RPRX
15.20%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
RPRX’s Return on Equity of 15.20% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
WAT
35.02%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
WAT’s Return on Equity of 35.02% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
RPRX
44.28%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
RPRX’s Net Profit Margin of 44.28% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
WAT
21.71%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
A Net Profit Margin of 21.71% places WAT in the upper quartile for the Life Sciences Tools & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
RPRX
79.84%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
RPRX’s Operating Profit Margin of 79.84% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
WAT
27.69%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
An Operating Profit Margin of 27.69% places WAT in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | RPRX | WAT |
|---|---|---|
| Return on Equity (TTM) | 15.20% | 35.02% |
| Return on Assets (TTM) | 5.66% | 14.40% |
| Net Profit Margin (TTM) | 44.28% | 21.71% |
| Operating Profit Margin (TTM) | 79.84% | 27.69% |
| Gross Profit Margin (TTM) | -- | 59.02% |
Financial Strength
Current Ratio (MRQ)
RPRX
1.26
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
RPRX’s Current Ratio of 1.26 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
WAT
1.75
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
WAT’s Current Ratio of 1.75 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
RPRX
1.26
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
RPRX’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.26. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
WAT
0.67
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
WAT’s Debt-to-Equity Ratio of 0.67 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
RPRX
4.70
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
RPRX’s Interest Coverage Ratio of 4.70 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
WAT
11.29
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
WAT’s Interest Coverage Ratio of 11.29 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | RPRX | WAT |
|---|---|---|
| Current Ratio (MRQ) | 1.26 | 1.75 |
| Quick Ratio (MRQ) | 1.26 | 1.22 |
| Debt-to-Equity Ratio (MRQ) | 1.26 | 0.67 |
| Interest Coverage Ratio (TTM) | 4.70 | 11.29 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
RPRX
1.76%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
RPRX’s Dividend Yield of 1.76% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
WAT
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
WAT currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
RPRX
36.87%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
RPRX’s Dividend Payout Ratio of 36.87% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
WAT
0.00%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
WAT has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | RPRX | WAT |
|---|---|---|
| Dividend Yield (TTM) | 1.76% | 0.00% |
| Dividend Payout Ratio (TTM) | 36.87% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
RPRX
21.00
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
RPRX’s P/E Ratio of 21.00 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
WAT
26.76
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
In the lower quartile for the Life Sciences Tools & Services industry, WAT’s P/E Ratio of 26.76 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
RPRX
9.30
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
With a P/S Ratio of 9.30, RPRX trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
WAT
5.81
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
WAT’s P/S Ratio of 5.81 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
RPRX
3.19
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
RPRX’s P/B Ratio of 3.19 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
WAT
9.62
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
At 9.62, WAT’s P/B Ratio is at an extreme premium to the Life Sciences Tools & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | RPRX | WAT |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 21.00 | 26.76 |
| Price-to-Sales Ratio (TTM) | 9.30 | 5.81 |
| Price-to-Book Ratio (MRQ) | 3.19 | 9.62 |
| Price-to-Free Cash Flow Ratio (TTM) | 17.80 | 28.57 |